2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a post hoc analysis

• John Vissing,
• Renato Mantegazza,
• Sabrina Sacconi,
• Julian Grosskreutz,
• Robert M Pascuzzi,
• Vera Bril,
• Ali A Habib,
• Tuan Vu,
• Bernhard Greve,
• Jeremy Welton,
• Raphaëlle Beau Lejdstrom,
• Fiona Grimson,
• Zabeen K Mahuwala,
• Thaïs Tarancón

Affiliations

John Vissing

9Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Renato Mantegazza

7Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy

Sabrina Sacconi

12 Peripheral Nervous System, Muscle and ALS Department, Université Côte d`Azur, Nice, France

Julian Grosskreutz

5Precision Neurology, Department of Neurology, University of Lübeck, Lübeck, Germany

Robert M Pascuzzi

3Neurology Department, Indiana University School of Medicine, Indiana University Health, Indianapolis, IN, USA

Vera Bril

15University Health Network, Toronto, ON, Canada

Ali A Habib

6MDA ALS and Neuromuscular Center, University of California, Irvine, Orange, California, USA

Tuan Vu

7Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA

Bernhard Greve

11UCB Pharma, Monheim, Germany

Jeremy Welton

17UCB Pharma, Malvern, VIC, Australia

Raphaëlle Beau Lejdstrom

7UCB Pharma, Bulle, Switzerland

Fiona Grimson

9UCB Pharma, Slough, UK

Zabeen K Mahuwala

6Department of Neuromuscular Medicine and Clinical Neurophysiology, University of Kentucky, Lexington, KY, USA

Thaïs Tarancón

14UCB Pharma, Madrid, Spain